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Abstract 13 
There is a high incidence of upper respiratory viral infections in the human population, with infection 14 
severity being unique to each individual. Upper respiratory viruses have been associated previously 15 
with secondary bacterial infection however, several cross-sectional studies analysed in the literature 16 
indicate that an inverse relationship can also occur. Pathobiont abundance and/or bacterial dysbiosis 17 
can impair epithelial integrity and predispose an individual to viral infection. In this review we 18 
describe common commensal microorganisms that have the capacity to reduce the abundance of 19 
pathobionts and maintain bacterial symbiosis in the upper respiratory tract and discuss the potential 20 
and limitations of localised probiotic formulations of commensal bacteria to reduce the incidence and 21 
severity of viral infections.  22 
1 Introduction 23 
The upper respiratory tract (URT) is the epicentre of the respiratory microbiota. As a ‘portal of entry’ 24 
into the respiratory system, the URT’s proximity to the external environment allows for adherence 25 
and colonisation of a diverse and abundant microbiota. A healthy upper respiratory microbiota works 26 
in synergy with its host, mainly colonising the anterior nares and nasopharynx to provide an innate 27 
barrier that defends against pathogens and modulates immune responses that occur from exposure to 28 
external triggers (Man et al., 2017;Hakansson et al., 2018). These external triggers include smoke, 29 
dust, allergens, chemical irritants, changes in temperature, and microorganisms (Burbank et al., 30 
2017). 31 
A variety of bacteria are found in the URT including commensals that are thought to promote a 32 
healthy epithelium, but also pathobionts that can be benign or pathogenic under certain 33 
circumstances. The most prevalent commensals include Corynebacterium spp., Dolosigranulum 34 
pigrum, Streptococcus mitis/oralis, Staphylococcus epidermis and Haemophilus haemolyticus, while 35 
pathobionts include Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus and 36 
Moraxella catarrhalis (Escapa et al., 2018). Viral infections can enable pathobionts to initiate 37 
secondary infections by damaging epithelial cells and inhibiting mucociliary clearance(Ahern and 38 
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Cervin, 2019). However, several cross-sectional studies analysed in the literature indicate that an 39 
inverse relationship may also occur, whereby pathobiont abundance and/or bacterial dysbiosis could 40 
cause impairment of epithelial integrity and predispose an individual to viral infection (Pitkaranta et 41 
al., 2006;Moore et al., 2010). Therefore, this review looks at the current research surrounding the 42 
URT microbiota, its influence on viral infection and the potential role of commensal bacteria in the 43 
prevention and management of viral upper respiratory infections. 44 
2 The airway epithelial barrier and innate responses to microorganisms 45 
Apart from its function in facilitating gas exchange, the airway epithelium also acts as a physical and 46 
chemical barrier against infection from microorganisms.  This is achieved through the combined 47 
action of the mucociliary escalator and the maintenance of a tight physical barrier.  Mucus is 48 
produced by goblet cells and can trap and neutralise microorganisms via mucins, antimicrobial 49 
proteins and immunoglobulins secreted from epithelial cells. Cilia on the apical surface of ciliated 50 
cells beat synchronously to move mucus and the microorganisms trapped within, away from the 51 
airways to expel them (Bergelson, 2009;Voynow and Rubin, 2009). The physical barrier is formed 52 
via proteins that promote tight cell-cell adhesion of epithelial cells including tight junctions (TJs), 53 
adherent junctions (AJs), gap junctions (GJs), and desmosomes (Rezaee and Georas, 2014). They 54 
form an impenetrable barrier preventing viral and bacterial entry through the epithelial layer, 55 
systemic spread through the circulation and access to viral receptors on the basolateral epithelial 56 
surface (Bergelson, 2009;Voynow and Rubin, 2009;Sharma et al., 2020).  57 
 58 
Epithelial and resident sensor cells including macrophages and dendritic cells can sense and respond 59 
to the presence of microorganisms via pattern recognition receptors (PRRs).  PRRs expressed by the 60 
respiratory epithelium include Toll-Like Receptors (TLRs), epidermal growth factor (EGF) and C-61 
type lectins.  PRRs recognise conserved microbial molecules such as components of bacterial and 62 
fungal cell walls, flagellin, viral RNA, as well as host cell components that indicate cell damage 63 
(Parker and Prince, 2011).  Sensing of bacterial, fungal and viral components initiates the release of 64 
signalling molecules (cytokines and chemokines) that drive the innate immune response (Invernizzi 65 
et al., 2020).  For example, stimulation of PRRs can modulate intercellular junctions (including TJs, 66 
GJs, AJs and desmosomes) through the upregulation of proinflammatory cytokines or epidermal 67 
growth factor (EGF) which can result in the weakening or strengthening of the respiratory epithelial 68 
barrier, respectively (Lebeer et al., 2010;Martens et al., 2018). 69 
 70 
Cytokines can act locally on epithelial cells to upregulate the expression of genes that contribute to 71 
pathogen clearance, like mucus production, antimicrobial peptides and interferons (Parker and 72 
Prince, 2011). Cytokines and chemokines also activate and recruit immune cells that perform a range 73 
of control mechanisms including phagocytosis and inflammation (Invernizzi et al., 2020). Interferons 74 
are particularly important for the control of viruses, as they signal the presence of a viral infection to 75 
surrounding cells and upregulate genes that restrict viral replication (Fensterl and Sen, 2009). These 76 
innate immune responses help protect against pathogen infection, however there are clearly different 77 
responses to commensal versus pathogenic microorganisms that enable the respiratory microbiota to 78 
colonise the epithelium without chronically stimulating an inflammatory immune response. 79 
 80 
While the microbiota is in part controlled by exclusion from the epithelium via the mechanisms 81 
described above, there is also evidence that commensals can directly stimulate immune tolerance and 82 
inhibit inflammatory signalling. For example, in the gut the commensal Bacteroidetes 83 
thetaiotaomicron can inhibit NF-kB expression in intestinal epithelial cells (Kelly et al., 2004) and 84 
the production of short chain fatty acids (SCFA) by Clostridium spp. stimulates the expansion of 85 
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anti-inflammatory T-regulatory cells (Tregs) (Atarashi et al., 2011).  Tregs are important modulators 86 
of immune tolerance, and their expansion and development is also stimulated directly via antigen 87 
recognition of specific commensal bacteria (Russler-Germain et al., 2017), suggesting the 88 
involvement of both innate and adaptive immune mechanisms in tolerance to the microbiota. These 89 
examples come from the gut, which has been more extensively characterized for host microbiota 90 
interactions, but it is likely that similar mechanisms exist in the URT.  While research on immune 91 
stimulation by respiratory commensals is scarce, studies with traditional probiotic strains of bacteria 92 
like Lactobacillus spp. have shown they can stimulate expansion of Tregs via contact with dendritic 93 
cells, resulting in increased expression of anti-inflammatory cytokines such as interleukin (IL)-10, 94 
and inhibition of proinflammatory cytokines including IL-2, IL-4, IL-5 and tumour necrosis factor 95 
alpha (TNF-α) (Martens et al., 2018). Commensals native to the URT are likely to similarly stimulate 96 
immunotolerance, suggesting it is possible to tune the host inflammatory state via manipulation of 97 
the resident microbiota. 98 
 99 
3 The URT microbiota 100 
The URT microbiota is dominated by bacteria from Actinobacteria and Firmicutes phyla, with 101 
smaller proportions of species from the Proteobacteria and Bacteroidetes. The URT is colonised by 102 
diverse communities of microorganisms, with changes in community structure associated with 103 
different anatomical locations and epithelial types (Yan et al., 2013;Proctor and Relman, 2017). The 104 
anterior nares are closest to the external environment and are lined with keratinized squamous 105 
epithelium, and sebaceous glands that secrete the host derived lipid and sebum (Man et al., 2017), 106 
while the sino-nasal and nasopharyngeal mucosa has a pseudostratified columnar and ciliated 107 
epithelium that produces mucus (Beule, 2010).   108 
Cutibacterium (previously Propionibacterium) and Corynebacterium spp. are lipophilic skin 109 
colonisers which along with Staphylococcus spp. commonly dominate in the anterior nares, while the 110 
nasal mucosa supports a greater diversity of bacteria including Moraxella, Dolosigranulum and 111 
Streptococcus spp. (Yan et al., 2013;Man et al., 2017). The nasopharynx contains patches of scattered 112 
respiratory epithelial cells but is mainly lined with stratified squamous epithelium (Man et al., 2017), 113 
like the nasal mucosa there are more abundant and diverse bacterial communities in the nasopharynx 114 
in comparison to the anterior nares (Yan et al., 2013). Dolosigranulum, Haemophilus and 115 
Streptococcus spp. are frequent colonisers of the nasopharynx which also commonly contains 116 
Moraxella, Corynebacterium and Staphylococcus spp. (Man et al., 2017).  117 
3.1 Development of the URT microbiota 118 
In the development of the URT microbiota, mode of delivery and type of infant feeding play a key 119 
role in the development of bacterial diversity and abundance (Esposito and Principi, 2018). Dominant 120 
organisms from the anterior nares (Staphylococcus, Corynebacteria and Cutibacterium are thought to 121 
be acquired via skin to skin contact (Esposito and Principi, 2018). These are also dominant taxa from 122 
the skin microbiota which is in close proximity to the anterior nares, suggesting that the microbiota 123 
of the skin influences the URT microbiota. Breast-fed infants were shown to have an increased 124 
abundance of Corynebacterium spp. in their URT in comparison to formula fed infants who showed 125 
an S. aureus dominated bacterial profile (Biesbroek et al., 2014a). Maternal breast milk has its own 126 
microbiota, in which Corynebacterium spp. is frequently detected, indicating that along with skin 127 
contact, breast feeding is another source of colonization with this taxa within the first few months of 128 
life (Zimmermann and Curtis, 2020). 129 
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D. pigrum is also abundant, but in lower quantities in comparison to the dominant three. D. pigrum is 130 
obtained in early development of the human upper respiratory microbiota, likely from vaginal 131 
microbiota acquired from a vaginal delivery (Esposito and Principi, 2018). An increased abundance 132 
of D. pigrum in infants was found to be associated with vaginal delivery as opposed to infants born 133 
by caesarean section and to be more abundant in the nasopharynx than in the anterior nares (Bosch et 134 
al., 2016;De Boeck et al., 2017). D. pigrum can produce lactic acid giving it the potential to lower the 135 
pH of the local environment which may select for Corynebacterium spp. growth, potentially 136 
explaining their co-occurrence within the upper respiratory tract (de Steenhuijsen Piters et al., 2015). 137 
Haemophilus spp. and Moraxella spp. also colonise the URT in early development, however the way 138 
they are acquired is not completely understood. In healthy development they have been shown to be 139 
particularly abundant in pre-schoolers in comparison to younger infants and older children (Bae et 140 
al., 2012). This may give some indication as to the time they are inoculated into the URT microbiota. 141 
The development of the URT microbiota in infancy is an important predictor of the frequency of 142 
respiratory infections in children (Teo et al., 2018;Dubourg et al., 2019) and may continue to play a 143 
role in respiratory health and disease later in life.  144 
4 The influence of pathobionts on URT viral infection 145 
URT infections (URTIs) include non-allergic rhinitis (the common cold), rhinosinusitis, pharyngitis, 146 
tonsillitis and otitis media. URTIs are a very common problem, especially among infants, children 147 
and elderly, and are one of the most frequent presentations in general practice (Cooke et al., 2013). 148 
URTIs can be caused by viruses or bacteria, however viral infections are the more dominant cause. 149 
Upper respiratory viruses that cause both rhinitis and/or sinusitis include human rhinovirus, 150 
respiratory syncytial virus, influenza and parainfluenza viruses, coronaviruses, adenoviruses and 151 
enteroviruses (Thomas and Bomar, 2021). While the ability of respiratory viruses to enable 152 
subsequent bacterial co-infections has been well established (Bakaletz, 2017), current evidence 153 
suggests that the inverse may also occur.  The expansion of different pathobionts in the URT 154 
microbiota may increase the incidence and severity of URT viral infections (Bosch et al., 2013).  155 
Dominance of a pathobiont in the URT microbiota can be considered as dysbiosis, which can be 156 
defined as either a loss of commensal microbes, the proliferation of pathobionts or a loss of total 157 
microbial diversity (Martens et al., 2018). Dysbiosis has been associated with impending, recurrent, 158 
and chronic disease (Man et al., 2017;Wilkins et al., 2019). URT dysbiosis could be caused by 159 
changes to the URT environment such as inflammation or the use of antibiotics.  Oral antibiotics 160 
have a significant impact on the gut microbiota (Schwartz et al., 2020), however the effect on the 161 
URT microbiota is less clear.  The concentration of antibiotic in the URT mucosa is likely to be 162 
lower than in the gut (Siu et al., 2019), and the reported effects of antibiotics on the URT are varied 163 
including increases (Merkley et al., 2015) or decreases (Liu et al., 2013) in microbial diversity, or no 164 
significant effects at all (Siu et al., 2021).  Interpretation of these studies is further complicated by 165 
differences in treatment and disease status of the subjects. The possibility that antibiotics or other 166 
medical treatments like steroids could cause dysbiosis and proliferation of pathobionts is an area for 167 
further study. 168 
Pathobionts are defined as bacteria that are commonly found in healthy asymptomatic individuals, 169 
but that can also be pathogenic under certain conditions. S. pneumoniae, H. influenzae, S. aureus and 170 
M. catarrhalis have been identified as bacterial pathobionts and an increased abundance of one or 171 
more of these are often features of dysbiosis in the URT (Bosch et al., 2013). An increased 172 
abundance of pathobionts often leads to a decrease in microbiota diversity, which is hypothesised to 173 
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contribute to a susceptible innate epithelial barrier and increased inflammation in response to 174 
environmental triggers including respiratory viruses (Esposito and Principi, 2018).  175 
Several mechanisms could explain the association of bacterial dysbiosis and viral infections. URT 176 
pathobionts can secrete products that impair ciliary action, reducing the capacity for mucociliary 177 
clearance (Janson et al., 1999;Shen et al., 2012). Secreted bacterial products (e.g., elastase) can also 178 
directly impact TJ proteins, reducing epithelial barrier function (Malik et al., 2015;Li et al., 2019). 179 
Alternatively, sensing pathobionts via TLRs can also downregulate TJ protein expression (Clarke et 180 
al., 2011). Disruption of barrier function may lead to increased accessibility of viral particles to the 181 
basolateral surface as an alternative entry point. Additionally, some pathobionts are known to 182 
upregulate the expression of viral receptor proteins in epithelial cells (Frick et al., 2000). These 183 
mechanisms are plausible ways by which the presence or increased abundance of pathobionts may 184 
help facilitate viral infections, above and beyond the ability of a virus to overcome the host’s innate 185 
immune defences. An overview of these mechanisms is illustrated in Figure 1. 186 
In the following sections we will summarise some of the known relationships where URT 187 
pathobionts enable or exacerbate infections by respiratory viruses.  188 
4.1 Respiratory syncytial virus (RSV) 189 
Respiratory syncytial virus (RSV) is a frequent cause of bronchiolitis in young children and older 190 
adults (Stensballe et al., 2006;Tin Tin Htar et al., 2020). RSV infects ciliated epithelial cells via 191 
binding of its G-protein with the receptor CX3CR1 (Tin Tin Htar et al., 2020). During in vitro co-192 
infection S. pneumoniae upregulates bacterial proteins such as superoxide dismutase, thioredoxin and 193 
histone-like DNA binding protein (hlpA) which protect S. pneumoniae against oxidative stress 194 
(Shadia et al., 2019). The protein hlpA, forms soluble antigen complexes with lipoteichoic acid that 195 
bind to epithelial cells and induce a proinflammatory cascade in the upper respiratory tract (Stinson et 196 
al., 1998). S. pneumoniae and RSV dominant profiles have been shown to be associated with greater 197 
levels of lipoteichoic acid (Chonmaitree et al., 2017). This inflammatory cascade results in an 198 
increased production of IL-6 and IL-8. These cytokines contribute to macrophage signalling and 199 
neutrophil recruitment which is associated with more severe symptoms of upper respiratory 200 
infections caused by respiratory syncytial virus (RSV) (Gulraiz et al., 2015). Inversely, gene 201 
expression in S. pneumoniae is affected by the presence of RSV, including an increase in the 202 
expression of virulent genes such as the pneumococcal toxin, pneumolysin, which is associated with 203 
virulent strains of S. pneumoniae (Smith et al., 2014). S. pneumoniae and RSV coinfection 204 
contributes to delayed recovery and indicates a synergism between the two microorganisms with 205 
negative consequences for the host (Brealey et al., 2018). 206 
4.2 Human rhinovirus (HRV) 207 
Human rhinovirus (HRV) is the most frequent cause of the common cold, and a common exacerbator 208 
of chronic respiratory diseases such as COPD and asthma (Jacobs et al., 2013;Blaas and Fuchs, 209 
2016).  H. influenzae has been found to increase the expression of the HRV receptor, intercellular 210 
adhesion molecule 1 (ICAM-1) in epithelial cells (Gulraiz et al., 2015). Upregulated ICAM-1 in 211 
respiratory epithelial cells increases the sensitivity of basolateral cells to HRV infection (Blaas and 212 
Fuchs, 2016). As a result, H. influenzae promotes higher viral loads of HRV therefore enhancing the 213 
inflammatory response (Gulraiz et al., 2015). Individuals with respiratory viruses and a high 214 
abundance of H. influenzae were found to suffer from more severe symptoms and increased 215 
radiological findings than with viral infection alone (Autio et al., 2015). In particular HRV was 216 
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shown to be associated with a microbiota with a high relative abundance of H. influenzae further 217 
reinforcing their relationship (Jacoby et al., 2007;van den Bergh et al., 2012). 218 
4.3 Influenzae virus 219 
S. aureus has long been observed in co-infections with influenza virus.  Influenza is known to 220 
promote S. aureus infection by modulation of the immune system (e.g. by depleting phagocytic cells 221 
(Ghoneim et al., 2013)) and increasing S. aureus adherence and internalization into host cells 222 
(Passariello et al., 2011).  This relationship goes both ways with S. aureus also enhancing influenza 223 
replication and infection severity, for example by the secretion of staphylokinase which enhances 224 
viral binding to host cells (Scheiblauer et al., 1992). Strains of S. aureus can produce enterotoxins A 225 
and B, that can disable cilia and therefore decrease mucociliary clearance (Min et al., 2006). This can 226 
lead to a host immune response, initiating the production of M1 alveolar macrophages (Hakansson et 227 
al., 2018). This in turn increases proinflammatory cytokines, TNF-α and IL-1B, and apoptosis of 228 
respiratory cells resulting in increased susceptibility to influenzae viral invasion into respiratory 229 
tissue. Inflammatory responses to influenzae infection and resulting URT symptoms such as rhinitis 230 
are likely heightened as a result of the increased bacterial load of S. aureus in the URT, which may 231 
occur in respiratory dysbiosis (Hakansson et al., 2018).  232 
4.4 Adenovirus/coronavirus 233 
An increased abundance of M. catarrhalis has been positively associated with occurrence of 234 
Adenovirus or Coronavirus (van den Bergh et al., 2012). These three microorganisms are commonly 235 
associated as predominant causes of otitis media (Moore et al., 2010). There currently isn’t much 236 
evidence supporting a symbiotic relationship in the literature. M. catarrhalis is known to utilise 237 
immunoglobulin D and hemagglutinin for the stimulation of high-density IgD-bearing B 238 
lymphocytes causing a proinflammatory response (de Vries et al., 2009). Also M. catarrhalis’ 239 
MAMPs can increase the expression of TLR-2 and subsequent transcription of proinflammatory 240 
genes (de Vries et al., 2009). TLR-2 upregulation also leads to a downregulation of IL-8 and a 241 
reduction in degranulation and chemotaxis of neutrophils which may increase the ability of 242 
Adenoviruses and Coronaviruses to adhere to respiratory epithelial cells and allow for a more severe 243 
URT viral infection due to a decreased neutrophilic response from the host.  244 
There have been several studies examining correlations between the URT microbiota and SARS-245 
CoV2 infection since the beginning of the COVID-19 global pandemic.  These studies indicate that 246 
the microbiota is shifted with an enrichment of pathobionts and opportunistic pathogens in COVID-247 
19 patients compared to non-infected individuals (Engen et al., 2021;Merenstein et al., 2021;Rhoades 248 
et al., 2021).  We note that at the time of writing, some of these studies have not yet been peer 249 
reviewed.  The microbiota was only sampled after infection with SARS-CoV2 was identified, so we 250 
don’t yet know whether pathobiont presence or expansion could increase the risk of SARS-CoV2 251 
infection, or if the infection itself might drive a microbiota shift.  However one study found that 252 
several Streptococcus spp. increase the expression of the ACE2 receptor protein in mammalian cells, 253 
indicating a possible mechanism by which pathobionts could influence the risk of infection (Xiong et 254 
al., 2021). 255 
All of the examples given above describe ways in which pathobionts may increase the risk or severity 256 
of a viral infection.  The ability to prevent or limit the colonisation of the URT by these pathobionts 257 
could therefore represent a viable strategy to reduce the risk of respiratory viral infection.   258 
 259 
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Commensal bacteria’s role in maintaining a healthy URT microbiota 260 
D. pigrum, Corynebacterium spp., S. epidermis, S. mitis/oralis and H. haemolyticus are commonly 261 
found in the URT microbiota and many observational studies have found associations with these 262 
bacteria and decreased risk or incidence of URT infections (see references provided below). In vitro 263 
studies have shown the ability of these URT colonisers to inhibit the growth of pathobionts (see 264 
references provided below), and a few human studies show the potential for this to occur in the 265 
respiratory tract (Uehara et al., 2000;Iwase et al., 2010;Kiryukhina et al., 2013). The ability to inhibit 266 
pathobionts could reduce the risk of viral respiratory infections given the evidence described above. 267 
Commensal respiratory bacteria could also influence the risk of viral infection through modulation of 268 
the host immune system or even through interaction with the virus itself (Dragelj et al., 2021). An 269 
overview of the evidence regarding interactions between commensal bacteria and pathobionts as well 270 
as the host immune system is given below and has been summarized in Table 1.  271 
5.1 Dolosigranulum pigrum and Corynebacterium spp. 272 
Species within the Dolosigranulum and Corynebacterium taxa have been associated with decreased 273 
rates of pathobionts and URT infections in a range of studies. Potential mechanisms include direct 274 
inhibition via production of antimicrobial compounds and competition for nutrients, and indirect 275 
inhibition via stimulation of the host immune system (de Steenhuijsen Piters and Bogaert, 276 
2016;Lappan and Peacock, 2019).  277 
In one longitudinal study, children resistant to acute otitis had a significantly higher abundance of D. 278 
pigrum and Corynebacterium spp. in their nasopharynx in comparison to children who suffered from 279 
acute otitis media (Lappan et al., 2018). Metagenomics of the resistant children further revealed C. 280 
pseudodiphtheriticum and D. pigrum to be dominant species in the nasopharynx of the resistant 281 
children, with C. propinquum and C. accolens present to a lesser extent (Lappan, 2019). In fact, 282 
correlations have been found in many observational studies where decreased relative abundance of 283 
Corynebacterium spp. and Dolosigranulum spp. was associated with increased risk of respiratory 284 
infections (Laufer et al., 2011;Biesbroek et al., 2014a;Biesbroek et al., 2014b), wheezing (Biesbroek 285 
et al., 2014a), symptomatic viral infections (Kloepfer et al., 2017), chronic rhinosinusitis (Cleland et 286 
al., 2016;Copeland et al., 2018), cystic fibrosis (Prevaes et al., 2016), and is inversely correlated with 287 
S. pneumoniae colonisation (Bomar et al., 2016). While there is some disparity in the literature, the 288 
majority of studies have found a negative correlation between Corynebacterium spp. and S. aureus 289 
relative abundance or carriage (Uehara et al., 2000;Lina et al., 2003;Yan et al., 2013) suggesting at 290 
least some species in this genus may be able to inhibit S. aureus colonization in the nose. There is 291 
thus a wealth of observational evidence to suggest that Corynebacterium and/or Dolosigranulum spp. 292 
in the respiratory microbiota may be beneficial. 293 
In vitro evidence exists to support the ability of Corynebacterium spp. to inhibit the growth and 294 
colonization of pathobionts in the respiratory tract. C. accolens can inhibit S. pneumoniae via 295 
liberation of free fatty acids from triacylglycerols found on the skin (Bomar et al., 2016), and clinical 296 
isolates of C. accolens can inhibit the growth of methicillin resistant S. aureus (Menberu et al., 297 
2021). C. pseudodiphtheriticum is inhibitory against M. catarrhalis and S. aureus (Hardy et al., 298 
2019;Lappan, 2019). Likewise, D. pigrum has been observed to inhibit both S. aureus and S. 299 
pneumoniae in vitro, in the latter case requiring spent media from Corynebacterium spp. for 300 
inhibition to occur (Brugger et al., 2020). Other mechanisms like downregulation of S. aureus 301 
virulence genes when co-cultured with Corynebacterium striatum have also been observed (Ramsey 302 
et al., 2016). 303 
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Apart from effects on the growth of pathobionts, Corynebacterium spp. may also mediate beneficial 304 
effects by modulation the immune system. Indirect evidence from humans suggests that 305 
Corynebacterium spp. may stimulate IFN-γ (de Steenhuijsen Piters and Bogaert, 2016) and this has 306 
also been observed in a mouse model where nasal inoculation with C. pseudodipthereticum increased 307 
resistance to RSV infection (Kanmani et al., 2017). IFN-γ stimulates antiviral functions in T-cells 308 
and natural killer cells.  Induction of IFN-γ could explain the decreased risk of upper respiratory viral 309 
infections when Corynebacterium spp. are in higher abundance in the URT microbiota (de 310 
Steenhuijsen Piters and Bogaert, 2016).  311 
Similarly D. pigrum and C. pseudodiptheriticum can modulate the immune response in mice.  Nasal 312 
administration of both species was shown to increase levels of the antiviral cytokines IFN-β and IFN-313 
γ, and the anti-inflammatory cytokine IL-10, however only particular strains of these species had an 314 
effect.  Further experiments with D. pigrum showed this effect was associated with reduce lung 315 
damage markers and increased resistance to RSV infection (Ortiz Moyano et al., 2020).  The same 316 
strain of D. pigrum was also found to increase expression of IFN-β as well as IL-6 in a bronchial 317 
epithelial cell lines (Calu-3) which was associated with reduced viral titres of SARS-CoV-2 and a 318 
reduction in cell cytotoxicity (Islam et al., 2021). 319 
5.2 Streptococcus salivaruis/oralis and Staphylococcus epidermis 320 
S. salivarius and S. oralis are commensal α-hemolytic streptococci that are found in the human 321 
nasopharynx of healthy individuals. These commensals produce diffusible bacteriocin molecules 322 
such as Colcin V and exhibit pH lowering traits that inhibit biofilm formation and activity (Bidossi et 323 
al., 2018). In intranasal administrative studies these commensals were found to be safe and well 324 
tolerated, and to reduce biofilm formation associated with upper respiratory tract pathobionts 325 
including S. aureus, S. pneumoniae and M. catarrhalis by up to 60% (Bidossi et al., 2018;De Grandi 326 
et al., 2019). 327 
Some strains of S. epidermis secrete high levels of extracellular serine protease (Esp) and these 328 
strains are negatively associated with S. aureus nasal colonization (Iwase et al., 2010). Esp degrades 329 
proteins involved in biofilm formation and colonisation, effectively disrupting S. aureus biofilms and 330 
leaving S. aureus susceptible to host antimicrobial peptides such as beta-defensin-2 (Sugimoto et al., 331 
2013). Inoculation of Esp producing S. epidermidis successfully eradicated S. aureus from human 332 
volunteers who had previously been consistently colonized (Iwase et al., 2010) validating it as a 333 
potential treatment option for the future consideration. S. epidermidis also has immunomodulatory 334 
properties. When inoculated in a murine infection model with influenza A virus infected cells, it 335 
increased IFN-γ production and suppressed replication of the virus (Kim et al., 2019). Future studies 336 
should investigate S. epidermidis in vivo in determining its effectiveness in reducing severity of S. 337 
aureus and influenza A proliferation.  338 
5.3 Haemophilus haemolyticus 339 
H. haemolyticus is a commensal URT bacteria which is phenotypically similar to H. influenzae and 340 
has historically been misidentified as such (Murphy et al., 2007). H. haemolyticus is capable of 341 
reducing H. influenzae attachment to epithelial cells (Pickering et al., 2016) and was recently shown 342 
to produce hemophilin (Latham et al., 2017;Latham et al., 2020). Hemophilin inhibits H. influenzae 343 
growth by binding to heme molecules that the pathobiont requires for growth (Latham et al., 2020). 344 
These mechanisms for competition and direct inhibition demonstrate H. haemolyticus has potential as 345 
a therapeutic probiotic. 346 
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It is clear that commensal microbiota in the URT have the potential to be used therapeutically to 347 
prevent pathobiont dominance and reduce the severity associated with dysbiosis in URT viral 348 
infections. 349 
6 Commensal bacteria as indirect options for prevention and management of upper 350 
respiratory viral infections 351 
The prevalence of upper respiratory infections signifies a key issue for the health care system, with 352 
annual costs in the billions (Fendrick et al., 2003). Some orally delivered probiotics, including 353 
bacteria derived from the human microbiota, have shown promising results for prevention or 354 
treatment of disease in both the gut and at other body sites (Hungin et al., 2018;Guo et al., 2019;Di 355 
Pierro et al., 2021). There is also some evidence that oral probiotics can help prevent or reduce the 356 
severity of URT infections (Hao et al., 2015;Wang et al., 2016). URT commensal bacteria have 357 
shown promise in vitro and may have potential as locally applied probiotics for the prevention and 358 
management of URT viral infections.  359 
6.1 Evidence and therapeutic use of commensals in clinical setting 360 
Manipulation of the microbiota can provide clinical benefits, including pathogen clearance and 361 
regulation of host immunity.  For example, faecal microbiota transplantation has become the most 362 
effective treatment of recurrent C. difficile infection with a 91% success rate without recurrence of 363 
infection (Baunwall et al., 2020).  Oral probiotics such as Lactobacillus and Bifidobacteria spp. have 364 
been shown to be beneficial for antibiotic induced diarrhea (Guo et al., 2019) and vaginal thrush 365 
(albeit with low evidence) (Xie et al., 2017).  The mechanisms behind these effects include the 366 
production of antimicrobial compounds (Vieco-Saiz et al., 2019), altering the local environment to 367 
promote commensal growth e.g. via acid production to lower pH (Islam, 2016), and effects on the 368 
host to increase immune tolerance via downregulation of inflammatory mediators (Gasta et al., 369 
2017). 370 
The natural oral probiotic, breast milk, has been associated with the development of a beneficial URT 371 
microbiota in infants (Lyons et al., 2020).  However, probiotics delivered orally would be less likely 372 
to influence URT microbial outcomes long term in an older person with an established microbiota 373 
where there is reduced capacity for adherence and colonisation (Esposito and Principi, 2018). 374 
Localised URT probiotics such as intranasal commensal inoculation would more likely have a greater 375 
inoculation rate and less systemic effects. Corynebacterium spp. and D. pigrum have many of the 376 
same features of currently used probiotics (pathogen inhibition, promotion of immune tolerance), 377 
indicating their potential use as localised sinonasal probiotics.  In URTIs that are chronic or recurrent 378 
due to pathobiont dominance, transplantation of commensal species may be an option to reset the 379 
balance of the microbiota which could reduce incidence and severity of viral URTIs. 380 
6.2 Studies on localised probiotics for the URT 381 
There are a limited number of studies regarding probiotics and their effect in URT disease. Some 382 
studies have focused on oral administration using innate commensal microbiota of the 383 
gastrointestinal tract such as Lactobacilli spp. and Bifidobacterium spp. This approach is predicated 384 
on the idea that gastrointestinal microbiota can influence the URT via systemic effects such as 385 
immune modulation, however the evidence from these studies for influence of the URT is mixed 386 
(Hao et al., 2015;Li et al., 2020).  387 
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Localised URT therapies can be easily applied as a spray or rinse and several studies have explored 388 
this route of administration. S. salivarius and S. mitis have been trialled as nasal sprays and their use 389 
was associated with reduction of episodes of URT infections (Bellussi et al., 2018;Shekhar et al., 390 
2019)(Shekhar et al. 2019; Bellussi et al. 2018). Specifically, intranasal immunisation of mice with S. 391 
mitis showed higher levels of IgG and IgA antibodies that are reactive to both S. mitis and S. 392 
pneumoniae resulting in reduced bacterial load of S. pneumoniae (Shekhar et al., 2019). The duration 393 
of these effects also needs to be considered. In a previous intranasal probiotic study a nasal spray 394 
containing 107 CFU per spray of S. sanguis, S. mitis, and S. oralis (in equal amounts) was detected 395 
for up to 12 hrs in the nasopharynx but not after 36 hrs (Tano et al., 2002). Even with daily 396 
application there was no significant effect in reducing the number of episodes in sufferers of 397 
recurrent acute otitis media, and it was proposed by the authors that without antibiotics to remove the 398 
natural microbiota and create an available niche for the probiotic, that they would be unlikely to 399 
adhere and change the microbiota permanently.  400 
Given the negative association of Corynebacterium spp. and S. aureus colonization, several 401 
Corynebacterium spp. have also been explored as a probiotic to remove S. aureus from the nose. A 402 
Corynebacterium sp. (Co304) was repeatedly inoculated into 17 healthy adults known to be 403 
colonized with S. aureus and found to eradicate S. aureus colonization in 12 of the participants, 404 
where controls of saline or S. epidermidis did not (Uehara et al., 2000). Similar results were seen in a 405 
smaller, uncontrolled study where inoculation of C. pseudodiphtheriticum was associated with 406 
removal of S. aureus from three out of four volunteers, and a reduction of S. aureus load in the fourth 407 
(Kiryukhina et al., 2013). This is likely to lead to the investigation of known commensals in vivo 408 
such as Corynebacterium spp. and D. pigrum that have both demonstrated significant favourable 409 
effects in vitro.   410 
7 Conclusions 411 
It is possible that upper respiratory viral pathogens benefit from increased abundances of one or more 412 
pathobiont bacterial species, as is often observed in URT microbiota dysbiosis (Bosch et al., 2013). 413 
Given the ability of commensal URT bacterial species to inhibit the growth or colonization of 414 
pathobionts, manipulation of the microbiota could be utilised as a preventative or treatment strategy 415 
in combating upper respiratory viral infections. With external triggers, along with medication use 416 
including antibiotics and steroids likely influencing the URT microbiota, further research into innate 417 
and preventative therapies may benefit individuals with chronic respiratory diseases that rely on these 418 
medications. Pathobiont abundance is increased during symptomatic but not asymptomatic viral 419 
infection, suggesting that symptomatic viral infections may be prevented, or their severity reduced if 420 
commensal bacteria are applied to reduce or prevent pathobiont abundance (Chonmaitree et al., 421 
2017).  422 
The commensal bacteria described above that show the potential to inhibit pathobionts and modulate 423 
host immunity should be further studied for their potential to stimulate a resilient sinonasal 424 
microbiota that is resistant to URT viral infection. The development of in vivo and in vitro models 425 
that assess microbial competition and interactions within the microbiota will further our 426 
understanding of the complex relationships that exist and bring us closer to developing probiotic 427 
solutions for URT infections. 428 
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Figure 1: Epithelial susceptibility to viruses during dysbiosis. (A) In a healthy URT where there is 789 
a diverse microbiota, higher numbers of commensal Microorganism-Associated Molecular Patterns 790 
(MAMPs) are able to attach to the Pattern Recognition Receptors (PRRs) of epithelial and dendritic 791 
cells resulting in maintenance of epithelial integrity and reduced susceptibility to viral infection. (B) 792 
Dysbiosis in the URT leads to an increase abundance of a pathobiont which increases the attachment 793 
of pathobiont MAMPs to the PRRs of epithelial and dendritic cells resulting in increased 794 
inflammation, reduced epithelial integrity. This leads to host cell damage which increases the 795 
susceptibility of host URT to viral infection. 796 
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13 Table 1: Association between commensal bacteria and bacterial pathobionts in the URT 797 
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